Baseline characteristics of patients receiving pembrolizumab plus dinaciclib
| Characteristic . | Pembrolizumab + dinaciclib . | |||
|---|---|---|---|---|
| rrCLL, n = 17 . | rrDLBCL, n = 38 . | rrMM, n = 17 . | All disease cohorts, N = 72 . | |
| Sex, n (%) | ||||
| Male | 14 (82.4) | 23 (60.5) | 6 (35.3) | 43 (59.7) |
| Female | 3 (17.6) | 15 (39.5) | 11 (64.7) | 29 (40.3) |
| Age, y | ||||
| , n (%) | 4 (23.5) | 19 (50.0) | 12 (70.6) | 35 (48.6) |
| , n (%) | 13 (76.5) | 19 (50.0) | 5 (29.4) | 37 (51.4) |
| Median (range) | 69.0 (50-85) | 64.5 (39-85) | 62.0 (42-74) | 65.0 (39-85) |
| Race, n (%) | ||||
| White | 16 (94.1) | 32 (84.2) | 14 (82.4) | 62 (86.1) |
| Asian | 0 (0.0) | 4 (10.5) | 0 (0.0) | 4 (5.6) |
| Black or African American | 1 (5.9) | 2 (5.3) | 3 (17.6) | 6 (8.3) |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 0 (0.0) | 4 (10.5) | 1 (5.9) | 5 (6.9) |
| Not Hispanic or Latino | 17 (100.0) | 34 (89.5) | 16 (94.1) | 67 (93.1) |
| Baseline ECOG PS, n (%) | ||||
| 0: normal activity | 8 (47.1) | 16 (42.1) | 8 (47.1) | 32 (44.4) |
| 1: symptomatic but ambulatory | 9 (52.9) | 22 (57.9) | 9 (52.9) | 40 (55.6) |
| Primary diagnosis, n (%) | ||||
| CLL, not otherwise specified | 17 (100.0) | 0 (0.0) | 0 (0.0) | 17 (23.6) |
| DLBCL, not otherwise specified | 0 (0.0) | 38 (100.0) | 0 (0.0) | 38 (52.8) |
| MM | 0 (0.0) | 0 (0.0) | 17 (100.0) | 17 (23.6) |
| Previous lines of therapy, n (%) | ||||
| 1 | 3 (17.6) | 0 (0.0) | 0 (0.0) | 3 (4.2) |
| 2 | 5 (29.4) | 16 (42.1) | 1 (5.9) | 22 (30.6) |
| 3 | 4 (23.5) | 8 (21.1) | 2 (11.8) | 14 (19.4) |
| 4 | 2 (11.8) | 10 (26.3) | 3 (17.6) | 15 (20.8) |
| 3 (17.6) | 4 (10.5) | 11 (64.7) | 18 (25.0) | |
| Previous therapies | ||||
| Antineoplastics, n (%) | ||||
| Bortezomib | 0 (0.0) | 0 (0.0) | 16 (94.1) | 16 (21.9) |
| Immunosuppressants, n (%) | ||||
| Lenalidomide | 0 (0.0) | 1 (2.6) | 17 (100.0) | 18 (24.7) |
| Pembrolizumab doses | ||||
| Median number | 3 | 3 | 2 | 3 |
| Time on study treatment, d | ||||
| Median (range) | 50 (1-492) | 51 (1-471) | 29 (8-71) | 49 (1-492) |
| Characteristic . | Pembrolizumab + dinaciclib . | |||
|---|---|---|---|---|
| rrCLL, n = 17 . | rrDLBCL, n = 38 . | rrMM, n = 17 . | All disease cohorts, N = 72 . | |
| Sex, n (%) | ||||
| Male | 14 (82.4) | 23 (60.5) | 6 (35.3) | 43 (59.7) |
| Female | 3 (17.6) | 15 (39.5) | 11 (64.7) | 29 (40.3) |
| Age, y | ||||
| , n (%) | 4 (23.5) | 19 (50.0) | 12 (70.6) | 35 (48.6) |
| , n (%) | 13 (76.5) | 19 (50.0) | 5 (29.4) | 37 (51.4) |
| Median (range) | 69.0 (50-85) | 64.5 (39-85) | 62.0 (42-74) | 65.0 (39-85) |
| Race, n (%) | ||||
| White | 16 (94.1) | 32 (84.2) | 14 (82.4) | 62 (86.1) |
| Asian | 0 (0.0) | 4 (10.5) | 0 (0.0) | 4 (5.6) |
| Black or African American | 1 (5.9) | 2 (5.3) | 3 (17.6) | 6 (8.3) |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 0 (0.0) | 4 (10.5) | 1 (5.9) | 5 (6.9) |
| Not Hispanic or Latino | 17 (100.0) | 34 (89.5) | 16 (94.1) | 67 (93.1) |
| Baseline ECOG PS, n (%) | ||||
| 0: normal activity | 8 (47.1) | 16 (42.1) | 8 (47.1) | 32 (44.4) |
| 1: symptomatic but ambulatory | 9 (52.9) | 22 (57.9) | 9 (52.9) | 40 (55.6) |
| Primary diagnosis, n (%) | ||||
| CLL, not otherwise specified | 17 (100.0) | 0 (0.0) | 0 (0.0) | 17 (23.6) |
| DLBCL, not otherwise specified | 0 (0.0) | 38 (100.0) | 0 (0.0) | 38 (52.8) |
| MM | 0 (0.0) | 0 (0.0) | 17 (100.0) | 17 (23.6) |
| Previous lines of therapy, n (%) | ||||
| 1 | 3 (17.6) | 0 (0.0) | 0 (0.0) | 3 (4.2) |
| 2 | 5 (29.4) | 16 (42.1) | 1 (5.9) | 22 (30.6) |
| 3 | 4 (23.5) | 8 (21.1) | 2 (11.8) | 14 (19.4) |
| 4 | 2 (11.8) | 10 (26.3) | 3 (17.6) | 15 (20.8) |
| 3 (17.6) | 4 (10.5) | 11 (64.7) | 18 (25.0) | |
| Previous therapies | ||||
| Antineoplastics, n (%) | ||||
| Bortezomib | 0 (0.0) | 0 (0.0) | 16 (94.1) | 16 (21.9) |
| Immunosuppressants, n (%) | ||||
| Lenalidomide | 0 (0.0) | 1 (2.6) | 17 (100.0) | 18 (24.7) |
| Pembrolizumab doses | ||||
| Median number | 3 | 3 | 2 | 3 |
| Time on study treatment, d | ||||
| Median (range) | 50 (1-492) | 51 (1-471) | 29 (8-71) | 49 (1-492) |